We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Assays Detect Inherited Blood Disorders Associated with Malaria

By LabMedica International staff writers
Posted on 07 Feb 2019
Plasmodium parasites have co-evolved with human hosts and exert a considerable evolutionary pressure on mutations that confer a degree of protection against malaria. More...
Glucose-6-phosphate dehydrogenase deficiency (G6PDd), hemoglobin C (HbC) and S (HbS) are inherited blood disorders (IBD) common in populations in malaria endemic areas.

All these IBDs are associated to some degree with protection against clinical malaria whilst additionally G6PDd is associated with hemolysis following treatment with 8-aminoquinolines. Measuring the prevalence of these inherited blood disorders in affected populations can improve understanding of disease epidemiology.

Scientists at the London School of Hygiene & Tropical Medicine (London, UK) and their international colleagues collected blood samples from males aged 18–45 years in Burkina Faso from August 2014 to November 2015 and from males aged over 10 years in The Gambia from December 2015 to April 2016. All participants were screened for glucose-6-phosphate enzyme activity using CareStart G6PD rapid diagnostic test and the Fluorescent Spot Test (FST).

Human DNA from whole blood samples was amplified in a novel, multiplex PCR reaction and extended with SNP-specific probes in an allele specific primer extension (ASPE) to simultaneously detect four epidemiologically important human markers including G6PD SNPs (G202A and A376G) and common hemoglobin mutations (HbS and HbC). The products were hybridized to magnetic beads and the median fluorescence intensity (MFI) was read on MAGPIX. Genotyping data was compared to phenotypical data generated by flow cytometry and to established genotyping methods. Samples were examined on a FACScailbur cytometer.

The team reported that 75/78 samples from Burkina Faso (96.2%) and 58/61 samples from The Gambia (95.1%) had a G6PD and a HBB genotype successfully assigned by the bead-based assay. Flow cytometry data available for 61 samples further supported the concordance between % G6PD normal/deficient cells and genotype. Using the microsphere assay for the four markers, data for 96 samples was available within seven hours at an estimated cost per sample of USD 4.30.

The authors concluded that the microsphere multiplex assay may play a role in addressing the increasing need to test for human and parasite genetic changes because of their impact on disease progression and malaria epidemiology. The multiplex nature of the assay in addition to the fast turn-around time and the relatively low cost, make it attractive for assessment of multiple genetic markers in large-scale epidemiological studies. The study was published on January 21, 2019, in the Malaria Journal.

Related Links:
London School of Hygiene & Tropical Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Automated Urinalysis Solution
UN-9000
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.